MA27021A1 - Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant - Google Patents

Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant

Info

Publication number: MA27021A1
Authority: MA; Morocco
Prior art keywords: triazatetracyclo; pentaene; hexadeca; citrate; pharmaceutical compositions
Prior art date: 2001-05-14

Application number

MA27390A

Other languages

English (en)

Inventor

Phillip James Johnson

Peter Robert Rose

Lewin Theophilus Wint

Glenn Robert Williams

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2003-11-10

Publication date

2004-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-10 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA27021A1 publication Critical patent/MA27021A1/fr

Links

KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Cardiology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Diabetes (AREA)
Psychology (AREA)
Obesity (AREA)
AIDS & HIV (AREA)
Anesthesiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)

MA27390A 2001-05-14 2003-11-10 Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant MA27021A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29086301P	2001-05-14	2001-05-14

Publications (1)

Publication Number	Publication Date
MA27021A1 true MA27021A1 (fr)	2004-12-20

Family

ID=23117854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27390A MA27021A1 (fr)	2001-05-14	2003-11-10	Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant

Country Status (37)

Country	Link
US (1)	US6787549B2 (fr)
EP (1)	EP1390366B1 (fr)
JP (1)	JP4137645B2 (fr)
KR (1)	KR20040008175A (fr)
CN (1)	CN1509288A (fr)
AP (1)	AP1429A (fr)
AR (1)	AR035889A1 (fr)
AT (1)	ATE303386T1 (fr)
BG (1)	BG108344A (fr)
CA (1)	CA2446988A1 (fr)
CZ (1)	CZ20032917A3 (fr)
DE (1)	DE60205888T2 (fr)
DO (1)	DOP2002000390A (fr)
DZ (1)	DZ3503A1 (fr)
EA (1)	EA005529B1 (fr)
EE (1)	EE200300557A (fr)
ES (1)	ES2245731T3 (fr)
GT (1)	GT200200081A (fr)
HR (1)	HRP20030911A2 (fr)
HU (1)	HUP0304085A3 (fr)
IL (1)	IL157874A0 (fr)
IS (1)	IS6956A (fr)
MA (1)	MA27021A1 (fr)
MX (1)	MXPA03010365A (fr)
MY (1)	MY134123A (fr)
NO (1)	NO20035035D0 (fr)
NZ (1)	NZ528209A (fr)
OA (1)	OA12600A (fr)
PA (1)	PA8545001A1 (fr)
PE (1)	PE20021095A1 (fr)
PL (1)	PL366774A1 (fr)
SK (1)	SK13372003A3 (fr)
TN (1)	TNSN03112A1 (fr)
UA (1)	UA73421C2 (fr)
UY (1)	UY27287A1 (fr)
WO (1)	WO2002092597A1 (fr)
ZA (1)	ZA200307234B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1044189E (pt) *	1997-12-31	2008-04-22	Pfizer Prod Inc	Compostos azapolicíclicos condensados com arilo
MXPA04003807A (es)	2001-11-30	2004-07-30	Pfizer Prod Inc	Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
EP1633358A1 (fr) *	2003-05-20	2006-03-15	Pfizer Products Inc.	Compositions pharmaceutiques a base de varenicline
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP2086977A2 (fr) *	2006-11-09	2009-08-12	Pfizer Products Inc.	Polymorphes d'intermédiaires nicotiniques
WO2009109651A1 (fr) *	2008-03-06	2009-09-11	Medichem, S.A.	Sels d'un dérivé de pyrazino[2,3-h][3]benzazépine
US8039620B2 (en)	2008-05-22	2011-10-18	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (fr) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Processus de préparation de varenicline et d'intermédiaires de ce composé
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
SG171907A1 (en) *	2008-12-11	2011-07-28	S Bio Pte Ltd	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
US20100189791A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
WO2010143070A2 (fr)	2009-06-10	2010-12-16	Actavis Group Ptc Ehf	Co-précipités amorphes de tartrate de varénicline
US8178537B2 (en)	2009-06-22	2012-05-15	Teva Pharmaceutical Industries Ltd.	Solid state forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (fr)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Sels de la varénicline et leurs formes cristallines
JP5925381B2 (ja)	2012-04-13	2016-05-25	▲連雲▼港金康和信▲薬業▼有限公司ＬｉａｎｙｕｎｇａｎｇＪｉｎｋａｎｇＨｅｘｉｎＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	化合物［４−（２−アミノ−１０−メチル−４−オキソ−６，７，８，９−テトラヒドロ−４ａ，７−エピミノピリミド［４，５−ｂ］［１，４］ジアゼピン−５（４Ｈ）−イル）ベンゾイル］−グルタメート及びその製造
WO2018154395A2 (fr)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Composition pharmaceutique à libération contrôlée de varénicline
EP3756653A1 (fr) *	2019-06-28	2020-12-30	Alfred E. Tiefenbacher (GmbH & Co. KG)	Citrate de varénicline à microparticules
JP2023520164A (ja) *	2020-03-16	2023-05-16	チョンドゥーサイマウントファーマテックカンパニーリミテッド	５－ｈｔ３受容体モジュレーター、結晶形態、それらの製造方法及び使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1044189E (pt) *	1997-12-31	2008-04-22	Pfizer Prod Inc	Compostos azapolicíclicos condensados com arilo
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

2002
- 2002-04-26 EP EP02724553A patent/EP1390366B1/fr not_active Expired - Lifetime
- 2002-04-26 HR HR20030911A patent/HRP20030911A2/xx not_active Application Discontinuation
- 2002-04-26 AT AT02724553T patent/ATE303386T1/de not_active IP Right Cessation
- 2002-04-26 ES ES02724553T patent/ES2245731T3/es not_active Expired - Lifetime
- 2002-04-26 DE DE60205888T patent/DE60205888T2/de not_active Expired - Fee Related
- 2002-04-26 OA OA1200300290A patent/OA12600A/en unknown
- 2002-04-26 EA EA200301120A patent/EA005529B1/ru not_active IP Right Cessation
- 2002-04-26 PL PL02366774A patent/PL366774A1/xx not_active Application Discontinuation
- 2002-04-26 WO PCT/IB2002/001450 patent/WO2002092597A1/fr not_active Ceased
- 2002-04-26 CN CNA028099117A patent/CN1509288A/zh active Pending
- 2002-04-26 KR KR10-2003-7014752A patent/KR20040008175A/ko not_active Ceased
- 2002-04-26 HU HU0304085A patent/HUP0304085A3/hu unknown
- 2002-04-26 UA UA20031110265A patent/UA73421C2/uk unknown
- 2002-04-26 JP JP2002589481A patent/JP4137645B2/ja not_active Expired - Fee Related
- 2002-04-26 DO DO2002000390A patent/DOP2002000390A/es unknown
- 2002-04-26 MX MXPA03010365A patent/MXPA03010365A/es active IP Right Grant
- 2002-04-26 CA CA002446988A patent/CA2446988A1/fr not_active Abandoned
- 2002-04-26 CZ CZ20032917A patent/CZ20032917A3/cs unknown
- 2002-04-26 SK SK1337-2003A patent/SK13372003A3/sk unknown
- 2002-04-26 IL IL15787402A patent/IL157874A0/xx unknown
- 2002-04-26 EE EEP200300557A patent/EE200300557A/xx unknown
- 2002-04-26 NZ NZ528209A patent/NZ528209A/en unknown
- 2002-04-26 DZ DZ023503A patent/DZ3503A1/fr active
- 2002-05-06 US US10/139,449 patent/US6787549B2/en not_active Expired - Fee Related
- 2002-05-09 AP APAP/P/2002/002522A patent/AP1429A/en active
- 2002-05-09 GT GT200200081A patent/GT200200081A/es unknown
- 2002-05-10 PE PE2002000392A patent/PE20021095A1/es not_active Application Discontinuation
- 2002-05-13 MY MYPI20021725A patent/MY134123A/en unknown
- 2002-05-13 AR ARP020101735A patent/AR035889A1/es unknown
- 2002-05-13 UY UY27287A patent/UY27287A1/es not_active Application Discontinuation
- 2002-05-14 PA PA20028545001A patent/PA8545001A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001450A patent/TNSN03112A1/fr unknown
- 2003-09-15 IS IS6956A patent/IS6956A/is unknown
- 2003-09-16 ZA ZA200307234A patent/ZA200307234B/en unknown
- 2003-11-10 MA MA27390A patent/MA27021A1/fr unknown
- 2003-11-11 BG BG108344A patent/BG108344A/bg unknown
- 2003-11-13 NO NO20035035A patent/NO20035035D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EE200300557A (et)	2004-04-15
IS6956A (is)	2003-09-15
US20030149091A1 (en)	2003-08-07
DZ3503A1 (fr)	2002-11-21
TNSN03112A1 (fr)	2005-12-23
MY134123A (en)	2007-11-30
NO20035035L (no)	2003-11-13
ZA200307234B (en)	2004-09-16
PA8545001A1 (es)	2003-09-05
UY27287A1 (es)	2003-02-28
DOP2002000390A (es)	2003-03-15
HUP0304085A3 (en)	2005-09-28
JP4137645B2 (ja)	2008-08-20
HUP0304085A2 (en)	2004-04-28
HRP20030911A2 (en)	2004-02-29
ATE303386T1 (de)	2005-09-15
CA2446988A1 (fr)	2002-11-21
BG108344A (bg)	2004-12-30
WO2002092597A1 (fr)	2002-11-21
AR035889A1 (es)	2004-07-21
DE60205888D1 (de)	2005-10-06
AP2002002522A0 (en)	2002-06-30
AP1429A (en)	2005-06-13
PL366774A1 (en)	2005-02-07
UA73421C2 (en)	2005-07-15
IL157874A0 (en)	2004-03-28
JP2004529186A (ja)	2004-09-24
NO20035035D0 (no)	2003-11-13
NZ528209A (en)	2004-09-24
DE60205888T2 (de)	2006-07-06
US6787549B2 (en)	2004-09-07
EA200301120A1 (ru)	2004-02-26
CZ20032917A3 (cs)	2004-07-14
EP1390366B1 (fr)	2005-08-31
EP1390366A1 (fr)	2004-02-25
MXPA03010365A (es)	2004-03-16
KR20040008175A (ko)	2004-01-28
EA005529B1 (ru)	2005-04-28
SK13372003A3 (sk)	2004-08-03
CN1509288A (zh)	2004-06-30
ES2245731T3 (es)	2006-01-16
OA12600A (en)	2006-06-09
GT200200081A (es)	2003-04-22
PE20021095A1 (es)	2002-12-14

Publication	Publication Date	Title
MA27020A1 (fr)	2004-12-20	Sels consistant en tartrates de 5,8,14-triazatetracyclo (10.3.1.0 .0)-hexadeca-2(11),3,5,7,9-pentaene et compositions pharmaceutiques les contenant.
EP1781257A4 (fr)	2012-06-20	Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
NO20042739L (no)	2004-07-23	Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
EP1246622A4 (fr)	2004-06-16	Nouvelles formes posologiques de benzimidazole substitue
FR2805818B1 (fr)	2002-04-26	Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
HUP0304085A2 (en)	2004-04-28	The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
WO2005039485A3 (fr)	2005-08-18	Inhibiteurs de gsk-3 et utilisations
MY144992A (en)	2011-12-15	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
IL170120A (en)	2013-04-30	4,2,1 - Triazines, their use in the preparation of HIV treatment or prophylaxis drugs, containing pharmaceutical preparations and methods for their preparation
PL374325A1 (en)	2005-10-17	Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
WO2001092283A3 (fr)	2002-07-04	Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie
CA2489140A1 (fr)	2004-11-18	Forme posologique contenant du pantoprazole en tant qu'ingredient actif
ITRM20030363A1 (it)	2005-01-25	Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
FR2846327B1 (fr)	2006-03-24	Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
WO2004098577A3 (fr)	2004-12-09	Forme posologique contenant du (s)-pantoprazole en tant qu'ingredient actif
PL368040A1 (en)	2005-03-21	Substituted 4-aminocyclohexanol derivatives
EP1697335A4 (fr)	2010-07-07	Derives de furancarbonylguanidine, leur preparation et compositions pharmaceutiques les contenant
RU2002121504A (ru)	2004-03-20	Лекарственные средства для лечения дегенеративного артрита
FR2826651B1 (fr)	2005-09-02	Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant
FR2843301B1 (fr)	2004-10-22	Forme galenique pour la delivrance colique de principes actifs
HRP20070441T3 (hr)	2007-10-31	Farmaceutska kombinacija za liječenje grčeva i/ili boli
RU2000113775A (ru)	2002-04-27	Препарат для профилактики и лечения эндометрита
SE9902674D0 (sv)	1999-07-12	New composition
FR2880886B1 (fr)	2007-04-06	Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
HN2002000112A (es)	2002-07-04	Sal citrato de 5, 8,14 - triazatetraciclo [10.3.1.02.11.04.9] - hexadeca - 2 (11),3,5,7,9 - pentaeno y composiciones farmaceuticas de la misma.